Intranasal vardenafil

After prostate surgery, the delicate nerves that control erections (called the cavernous nerves) can be affected. This disruption reduces normal blood and oxygen flow to the penis, which over time can lead to muscle loss and scarring (fibrosis) within the erectile tissue.

Recovery of erectile function depends on

• • nerve healing
  • maintaining healthy blood flow
  • oxygenation

Nitric oxide signalling is the central biological mechanism that allows penile smooth muscle relaxation, leading to blood flow and erection.

Intranasal drug delivery allows the medication to be absorbed quickly through the rich blood supply in the nasal passages—bypassing the liver’s first-pass metabolism that can slow or reduce oral drug effects.

This means the medication can reach effective levels in the bloodstream within minutes, making it ideal for on-demand use when a rapid response is needed.

Early clinical studies show that intranasal vardenafil achieves peak blood concentrations faster and more predictably than the standard 10 mg oral tablet, offering a convenient and fast-acting alternative.

Vardenafil’s potency, moderate lipophilicity, and molecular properties make it amenable to nasal formulations that can achieve comparable plasma exposure at lower doses, improving tolerability for some men (reduced gastrointestinal adverse effects compared with oral dosing). Early clinical pharmacokinetic work supports these advantages.

• Pharmacokinetics (humans): Randomized, cross-over pharmacokinetic studies report faster Tmax and comparable or higher early plasma exposure with intranasal vardenafil vs oral tablet in healthy men. This supports the drug’s on-demand potential.

• Preclinical (CNI models): Animal models of cavernous nerve injury show therapies that restore NO signalling or tissue oxygenation improve intracavernosal pressure responses; intranasal PDE5 inhibitor strategies are biologically plausible adjuncts for rehabilitation.

• Combination therapy context: Systematic reviews show benefit from combination strategies (PDE5 inhibitors plus other therapies) for difficult-to-treat ED, supporting trials that test intranasal vardenafil combined with other rehabilitative modalities.

• On-demand use — fast onset for planned sexual activity.

• Penile rehabilitation adjunct — intermittent dosing to improve nocturnal oxygenation and reduce fibrosis while neural recovery occurs.

• Option for oral-intolerant patients — lower systemic exposure and fewer GI side effects may improve adherence.

Key items to evaluate in long-term trials: nasal mucosal tolerance, local vascular effects in the nasal mucosa, consistent delivery across patients, and interaction with cardiovascular comorbidity. Early studies report minimal nasal irritation with appropriately designed carriers, but larger safety datasets are still needed.

• Well-powered randomized trials in post-prostatectomy patients measuring erectile function recovery (IIEF—International Index of Erectile Function scores), time to penetration-capable erections, and objective physiologic endpoints (nocturnal penile tumescence, intracavernosal pressure in mechanistic studies).

• Long-term safety for chronic/intermittent nasal administration.

• Comparative effectiveness vs standard oral PDE5 inhibitor therapy and combined rehabilitation protocols (e.g., low-intensity shockwave therapy, intracavernosal therapy, stem cell approaches).

• Pharmacokinetics comparison of vardenafil as administered by an intranasal spray formulation vs a 10-mg oral tablet. The Journal of Sexual Medicine (2023). OUP Academic

• Pharmacokinetics of an oral versus intranasal delivered formulation of the phosphodiesterase type 5 inhibitor vardenafil in healthy men – Phase 1 randomized crossover study. (ScienceDirect / EJPS 2025 preprint/early article). ScienceDirect+1

• Mechanisms and treatment of cavernous nerve injury-induced erectile dysfunction. Frontiers in Physiology (2022). (Review on CNI pathophysiology & rehabilitation). Frontiers

• Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: systematic review and meta-analysis. JAMA Network Open (2020). (Context for combination approaches including PDE5 inhibitor adjuncts). JAMA Network

• Phase 1 pilot / pharmacokinetic data and abstracts (EuropePMC / physiology journals) on intranasal vardenafil formulations and user-friendly pharmacokinetics. (EuropePMC entry citing pilot clinical PK data). Europe PMC